Research programme: antibacterials - Essential Therapeutics/Schering-Plough
Latest Information Update: 29 Aug 2007
At a glance
- Originator
- Developer Essential Therapeutics [CEASED]; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
- 04 Oct 2004 Essential Therapeutics has closed down
- 09 Nov 2001 Microcide Pharmaceuticals has merged with Althexis to form Essential Therapeutics